Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Genmab A/S Sponsored ADR (GMAB : NSDQ)

• Company Description    Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark. Number of Employees: 3,029

• Price / Volume Information    Yesterday's Closing Price: $27.75 Daily Weekly Monthly 20 Day Moving Average: 1,417,027 shares Shares Outstanding: 642.51 (millions) Market Capitalization: $17,829.57 (millions) Beta: 0.97 52 Week High: $35.43 52 Week Low: $17.24 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.87% 4.71% 12 Week -18.26% -13.74% Year To Date -9.90% -6.72%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL CARL JACOBSENS VEJ 30 - VALBY,G7 2500 DNK ph: 45-7020-2728 fax: - ir@genmab.com http://www.genmab.com

• General Corporate Information    Officers Jan G. van de Winkel - President and Chief Executive Officer Deirdre P. Connelly - Chair Anthony Mancini - Chief Operating Officer Anthony Pagano - Executive Vice President and Chief Financial Offic Birgitte Stephensen - Executive Vice President and Chief Legal Officer Peer Information Genmab A/S Sponsored ADR (CORR.) Genmab A/S Sponsored ADR (RSPI) Genmab A/S Sponsored ADR (CGXP) Genmab A/S Sponsored ADR (BGEN) Genmab A/S Sponsored ADR (GTBP) Genmab A/S Sponsored ADR (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 372303206 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/14/26 Share - Related Items Shares Outstanding: 642.51 Most Recent Split Date: (:1) Beta: 0.97 Market Capitalization: $17,829.57 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.33 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $1.17 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: 18.91% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/14/26

• Fundamental Ratios P/E Current FY Estimate: 23.63 Trailing 12 Months: 17.90 PEG Ratio: 1.25 Price Ratios Price/Book: 3.05 Price/Cash Flow: 17.24 Price / Sales: 4.79 EPS Growth vs. Year Ago Period: -91.23% vs. Previous Quarter: -92.31% Sales Growth vs. Year Ago Period: 14.84% vs. Previous Quarter: 3.52% ROE 03/31/26 - - 12/31/25 - 17.35 09/30/25 - 24.18 ROA 03/31/26 - - 12/31/25 - 11.69 09/30/25 - 19.62 Current Ratio 03/31/26 - - 12/31/25 - 2.02 09/30/25 - 6.03 Quick Ratio 03/31/26 - - 12/31/25 - 2.01 09/30/25 - 6.01 Operating Margin 03/31/26 - - 12/31/25 - 25.89 09/30/25 - 36.25 Net Margin 03/31/26 - - 12/31/25 - 25.89 09/30/25 - 41.36 Pre-Tax Margin 03/31/26 - - 12/31/25 - 32.37 09/30/25 - 46.49 Book Value 03/31/26 - - 12/31/25 - 9.10 09/30/25 - 8.96 Inventory Turnover 03/31/26 - - 12/31/25 - 16.70 09/30/25 - 17.08 Debt-to-Equity 03/31/26 - - 12/31/25 - 0.86 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - - 12/31/25 - 46.10 09/30/25 - 0.00

Powered by Zacks Investment Research ©